|
|
 |
|
Viewing report
|
|
|
|
Payer Agreements: Splitting the Risk
FirstWord Publishing, Oct 2011, Pages: 41
Budgets are tight. Payer funding for new products is dwindling. And for pharmaceutical companies, market access is more and more difficult to attain.
Across the UK, the US, Canada, Australia and parts of Europe, payer schemes are increasingly de rigueur. Schemes advanced by pharmaceutical companies either aim to grapple financial issues such as price volume agreements, or they tackle uncertainty by addressing increased data collection.
Report Overview
In Payer Agreements: Splitting the Risk, FirstWord Dossier offers a complete and concise overview of payer schemes by definition and category. Based on an array of expert interviews, the report discusses the key drivers behind the evolution of payer schemes from financial imperatives to market uncertainty. Most importantly, the report defines—country by country—emerging trends based on current case studies and tackles the big question: What are the key features that will ensure success?
Key features
- Detailed examination of the role of agreements in global pricing, reimbursement and market access
- Discussion of the drivers for schemes, including HTA and financial challenges
- Country-by-country trends illustrated with case studies
- Expert insight into the role of schemes and their evolution
- Analysis of the pros and cons of agreements
Key Benefits
- Definitions and categories of schemes
- Expert insight from key regulatory bodies
- Comprehensive references to key literature
Key Questions Asked
- What principles should be used in designing schemes?
- When should companies offer risk-sharing agreements?
- How can European risk-sharing be implemented in the US?
- What is the current state of play with schemes globally?
- What changes are likely in the future?
Who Should Read This Report
- Market access directors and managers
- Health economics professionals
- Pharmacoeconomics professionals
- Health Outcomes / Outcomes Research professionals
- Pricing and Reimbursement teams
- Government and regulatory affairs analysts
- Marketing research/business intelligence managers
- Government and regulatory affairs analysts
Expert Views
- Alicia Granados: MD. Senior Director Global HTA Strategy, GMA Genzyme
- Andrea Rappagliosi: Vice President European Government Affairs & Head of Brussels Office, GlaxoSmithKline
- Andrew Hobbs: Managing Director, Pope Woodhead and Associates Limited
- Ansgar Hebborn: Global Head, Payer and HTA Programme Policy, Roche
- Clare McGrath: Senior Director HTA Policy, Pfizer
- David Grainger: Global Public Policy Director, Lilly
- Günter Harms: Market Access & Public Affairs Director, Shire Human Genetic Therapies
- Kalipso Chalkidou: Director of International Division, National Institute for Health and Clinical Excellence
- Karen Facey: Evidence based health policy consultant and non-executive Director at NHS Forth Valley, and Chair of the HTAi Interest Group for Patient/Citizen Involvement in HTA
- Larry Gorkin: President, Gorkin and Cheddar Consulting
- Mel Walker: Senior Director Value Expert Engagement & Collaborations, GlaxoSmithKline
- Robert Nauman: Principal, BioPharma Advisors
- Ulf Staginnus: Head of Pricing & Health Economics Europe, Novartis
Key quotes:
“The current international pharmaceutical pricing framework is far too rigid. Manufacturers willing to openly differentiate the price for a given product in line with the different ability of various payers to afford a product will be punished by the consequences of international price referencing. At the same time, price systems are barely capable of differentiating the price for a single product that is used in multiple indications according to its different value propositions.”
– Ansgar Hebborn, Global Head, Payer and HTA Programme Policy, Roche
“Imagine in a time where those schemes could be really connected to one server. Like right at the patient's bed people would enter the data and so you would constantly be able to adjust and see performance and see small performance even in changes of dosing or changes or things. I know it's very difficult but I think eventually we might get there.”
– Ulf Staginnus, Head of Pricing & Health Economics Europe, Novartis
“There is a lot of difference in the governance across Europe, which ultimately leads to quality of HTA. An important aspect is of course the independence of the assessment from the appraisal and ultimately the decision on a certain price. That's very, very different country by country and region by region.”
– Ansgar Hebborn, Global Head, Payer and HTA Programme Policy, Roche
|
|
|
|
